Synonym
BOF4272; Bof-4272; Sodium-8-(3-methoxy-4-phenylsulfinylphenyl)pyrazolo (1,5-a)-1,3,5-triazine-4-olate monohydrate; 142181-44-0; 2Q33D25ZXE
IUPAC/Chemical Name
sodium 8-(3-methoxy-4-(phenylsulfinyl)phenyl)pyrazolo[1,5-a][1,3,5]triazin-4-olate
InChi Key
OYINCFAELBUAIS-UHFFFAOYSA-M
InChi Code
InChI=1S/C18H14N4O3S.Na/c1-25-15-9-12(14-10-21-22-17(14)19-11-20-18(22)23)7-8-16(15)26(24)13-5-3-2-4-6-13;/h2-11H,1H3,(H,19,20,23);/q;+1/p-1
SMILES Code
COC1=C(S(C2=CC=CC=C2)=O)C=CC(C3=C4N=CN=C([O-])N4N=C3)=C1.[Na+]
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
388.38
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Naito S, Nishimura M. Biotransformation of the xanthine oxidase inhibitor
BOF-4272 and its metabolites in the liver and by the intestinal flora in rat.
Xenobiotica. 2000 Jan;30(1):103-9. doi: 10.1080/004982500237866. PMID: 10659955.
2: Naito S, Nishimura M, Jin Y. Biotransformation of BOF-4272, a sulfoxide-
containing drug, in the cynomolgus monkey. Eur J Drug Metab Pharmacokinet. 1999
Jul-Sep;24(3):279-86. doi: 10.1007/BF03190032. PMID: 10716068.
3: Naito S, Nishimura M, Yoshitsugu H, Nogawa H. Metabolic pathways and
pharmacokinetics of BOF-4272, a sulfoxide-containing drug, in the dog: in vivo
and in vitro studies. Biol Pharm Bull. 1999 Dec;22(12):1391-5. doi:
10.1248/bpb.22.1391. PMID: 10746178.
4: Naito S, Nishimura M, Nogawa H. Pharmacokinetics of BOF-4272, a xanthine
oxidase inhibitor, after single intravenous or oral administration to male mice
and rats. J Pharm Pharmacol. 1999 Mar;51(3):347-51. doi:
10.1211/0022357991772358. PMID: 10344637.
5: Yamamoto T, Moriwaki Y, Suda M, Nasako Y, Takahashi S, Hiroishi K, Nakano T,
Hada T, Higashino K. Effect of BOF-4272 on the oxidation of allopurinol and
pyrazinamide in vivo. Is xanthine dehydrogenase or aldehyde oxidase more
important in oxidizing both allopurinol and pyrazinamide? Biochem Pharmacol.
1993 Dec 14;46(12):2277-84. doi: 10.1016/0006-2952(93)90618-7. PMID: 8274161.
6: Naito S, Nishimura M. Enantioselective uptake of BOF-4272, a xanthine oxidase
inhibitor with a chiral sulfoxide, by isolated rat hepatocytes. Yakugaku Zasshi.
2001 Dec;121(12):989-94. doi: 10.1248/yakushi.121.989. PMID: 11766411.
7: Naito S, Nishimura M. Stereoselective pharmacokinetics of BOF-4272 racemate
after oral administration to rats and dogs. Biol Pharm Bull. 2002
May;25(5):674-7. doi: 10.1248/bpb.25.674. PMID: 12033515.
8: Naito S, Nishimura M, Tamao Y. Evaluation of the pharmacological actions and
pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, in mouse liver. J
Pharm Pharmacol. 2000 Feb;52(2):173-9. doi: 10.1211/0022357001773823. PMID:
10714947.
9: Shibukawa A, Kadohara M, He JY, Nishimura M, Naito S, Nakagawa T. Study of
the enantioselective binding between BOF-4272 and serum albumins by means of
high-performance frontal analysis. J Chromatogr A. 1995 Mar 3;694(1):81-9. doi:
10.1016/0021-9673(94)00653-q. Erratum in: J Chromatogr A 1995 Aug 4;708(2):364.
PMID: 7719472.
10: Uematsu T, Nakashima M. Pharmacokinetic and pharmacodynamic properties of a
novel xanthine oxidase inhibitor, BOF-4272, in healthy volunteers. J Pharmacol
Exp Ther. 1994 Aug;270(2):453-9. PMID: 8071837.
